Pharmacy benefit manager Abarca and Amgen have reportedly entered into an outcomes-based contract for the drug Repatha.
Amgen’s Repatha is a cholesterol-lowering drug.
According to a press release, the “agreement is the first of its kind involving Amgen’s Repatha and a standalone PBM.”
“In the future, our payers and members will only pay for therapies that deliver expected outcomes and provide meaningful clinical value,” Abarca Chief Executive Officer Jason Borschow said in a statement. “We are proud to partner with Amgen, a company that stands by its products, to make this a reality today for the clients and members we serve.
Abarca also recently announced an outcomes-based deal with Biogen, and is reportedly working with several drug manufacturers to develop similar contracts.